Table 2. Characteristics of the patient groups in the study.
| Characteristics | VAP(+) | VAP(−) | P-value |
|---|---|---|---|
| Sample size | 32 | 68 | |
| Average age [years] | 64 ± 12 | 60 ± 14.5 | 0.16 |
| Male/Female | 26/6 | 44/24 | 0.07 |
| SOFA at time of BAL | 6.4 ± 3.4 | 6.9 ± 2.9 | 0.41 |
| Severe sepsis | 11 (34%) | 24 (35%) | 0.93 |
| ICU mortality | 12 (38%) | 31 (45%) | 0.45 |
| In hospital mortality | 14 (43%) | 37 (54%) | 0.34 |
| Diagnostic group at admission (p-value = 0.24) | |||
| Gastrointestinal | 4 (13%) | 9 (13%) | |
| Cardiovascular | 9 (28%) | 13 (19%) | |
| Hematologic | 3 (9%) | 15 (22%) | |
| Neurologic | 4 (13%) | 6 (9%) | |
| Orthopaedic/trauma | 4 (13%) | 2 (3%) | |
| Respiratory | 8 (25%) | 20 (29%) | |
| Other | 0 (0%) | 3 (4%) | |
| Presence of comorbidities (p-value = 0.80) | |||
| No comorbidity | 17 (53%) | 38 (56%) | |
| One comorbidityTwo comorbidities | 8 (25%)5 (16%) | 15 (22%)12 (18%) | |
| ≥Three comorbidities | 2 (6%) | 3 (4%) | |
| Distribution of comorbidities (p-value = 0.23) | |||
| cardiovascular | 3 (9%) | 3 (4%) | |
| respiratory | 3 (9%) | 5 (7%) | |
| chronic renal failure | 4 (13%) | 7 (10%) | |
| active malignancy | 2 (6%) | 9 (13%) | |
| immunocompromised | 7 (22%) | 15 (22%) | |
| neurologic impairment | 3 (9%) | 8 (12%) | |
| chronic liver failure | 2 (6%) | 2 (3%) | |
The age and SOFA scores were tested for significance with a two-sided paired t-test; significance was tested for the diagnostic groups using a Chi Square test. P < 0.05 was considered significant. Age and SOFA scores are represented as mean ± standard deviation.